The KIF2A Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human liver adenocarcinoma cell line SK-HEP-1, with targeted disruption of the KIF2A gene. This product offers a heterogeneous pool of modified cells, each carrying distinct gene-editing events that ablate KIF2A function, providing a powerful loss-of-function model for studying mitotic regulation and liver cancer biology. The polyclonal format retains genetic diversity, enabling robust analysis of KIF2A-dependent phenotypes without clonal selection artifacts. Researchers can employ this model to interrogate microtubule dynamics, chromosome segregation, and cell cycle checkpoints in a hepatocellular carcinoma context.
SK-HEP-1 is an established human hepatocellular carcinoma cell line originally isolated from a liver adenocarcinoma, widely utilized in liver cancer research due to its tumorigenic properties and well-characterized molecular landscape. It serves as a relevant in vitro system for investigating oncogenic signaling, drug resistance, and mitotic vulnerabilities in hepatic tumors. The knockout of KIF2A in this background allows dissection of kinesin-13 family functions specifically within the malignant hepatic milieu, offering insights into the interplay between microtubule regulatory proteins and hepatocellular carcinogenesis.
KIF2A encodes a kinesin-13 family motor protein that catalyzes microtubule depolymerization at plus ends, a critical activity for mitotic spindle dynamics, kinetochore microtubule turnover, and chromosome alignment. Its function is tightly regulated by upstream mitotic kinases, including Aurora A, Aurora B, PLK1, and CDK1, and is influenced by the tumor suppressor TP53. KIF2A operates downstream of these regulators, driving catastrophe events at microtubule tips. It physically interacts with KIF18A, KIFC1 (HSET), TPX2, and the plus-end tracking protein EB1, forming complexes that modulate spindle pole focusing and chromosome congression. This molecular network positions KIF2A as a central node in the mitotic spindle assembly checkpoint, linking microtubule dynamics to faithful chromosome segregation.
In the SK-HEP-1 hepatic cancer context, KIF2A knockout impairs mitotic progression by disrupting microtubule depolymerization at kinetochores and spindle poles, leading to chromosome missegregation, prolonged mitosis, and potential cell cycle arrest or apoptosis. This deficiency models the mitotic dysregulation commonly observed in hepatocellular carcinoma, where centrosome amplification and spindle abnormalities contribute to aneuploidy and genomic instability. The polyclonal knockout population recapitulates heterogeneous loss-of-function phenotypes, making it suitable for evaluating mitotic catastrophe induction and identifying synthetic lethal interactions with chemotherapeutic agents targeting the mitotic machinery.
This KIF2A knockout model supports diverse research applications, including investigation of mitotic spindle regulation in liver cancer, live-cell imaging of microtubule dynamics and chromosome movements, and flow cytometric analysis of cell cycle perturbations. Representative assays include Western blotting to confirm KIF2A depletion, immunofluorescence for spindle morphology assessment, apoptosis detection via Annexin V staining, colony formation assays to gauge long-term proliferation effects, and microtubule depolymerization assays to directly measure catalytic activity. It also enables drug target validation studies for Aurora kinase inhibitors and other mitotic poisons. For additional information, please contact Ascent Research.
